Results 211 to 220 of about 3,030,328 (299)

FGFR2 residence in primary cilia is necessary for epithelial cell signaling. [PDF]

J Cell Biol
Nita A, Abraham SP, Elrefaay ER, Fafilek B, Cizkova E, Ursachi VC, Gudernova I, Koudelka A, Dudeja P, Gregor T, Feketova Z, Rico G, Svozilova K, Celiker C, Czyrek AA, Barta T, Trantirek L, Wiedlocha A, Krejci P, Bosakova M.   +19 more
europepmc   +1 more source

Cell Signaling

Cell, 2000
openaire   +1 more source

Cell Signalling [PDF]

The Journal of Physiology, 2003
openaire   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Extracellular metallothionein: An alarmin regulating lymphocyte gene expression, cell signaling, and immune function. [PDF]

Cell Stress Chaperones
Maltz-Matyschsyk M, Melchiorre CK, Dostie-Laprise K, Lynes MA.   +3 more
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Bulk RNA Sequencing Reveals Signature Differences in Key Cell Signaling Pathways Between Porcine Venous and Arterial Smooth Muscle Cells. [PDF]

Int J Mol Sci
Lee KA, Li W, Uriyanghai U, Wai C, Su H, Yang A, Li L, Sudarsanam VA, Poulton JS, Roy-Chaudhury P, Xi G.   +10 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation. [PDF]

J Transl Med
Gonzalez-Garcia P, Moares N, Serrano-García I, Fernandez-Cisnal R, Luna-Espejo R, Ocaña-Cuesta J, Yi-He W, Muñoz-Miranda JP, Gabucio A, Fernandez-Ponce CM, Garcia-Cozar F.   +10 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source